SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The project is a derivative of Fartcoin. The Fartcoin deployer has deployed this token because the President at Bone Fide Wealth tweeted about "A client just called and asked me if there’s going to be a Fartcoin ETF this year." Since the Elon narrative is has been running this one has come to existence. The token is following different narratives like Fartcoin, SPX500 and other big memes following the Trump narrative.

Elon Trump Fart

ETF500.X is trending as the community rallies around the project, calling for a pump and highlighting its potential as the first ETF on Solana. Increased volume and accumulation are fueling optimism, though some caution against potential scams. Discussions also involve related meme coins like UPDOG and FARTCOIN.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is trending as the community anticipates potential gains, drawing attention to its connection with AI and autonomous agent technology. Grok's (Elon Musk AI) recommendations have fueled speculation about substantial returns, with community members actively discussing potential catalysts and real-world applications. The broader narrative focuses on Fetch.ai's role in the AI and crypto space, with some suggesting it's undervalued despite recent market fluctuations.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE.X is gaining traction as a community-driven meme coin, with many highlighting its solid community and potential for growth. Conversations revolve around its strong connection to internet culture and references to trending on UpDog. Investors are expressing bullish sentiment, anticipating further upward momentum.

The national debt has increased every year for the past ten years, and interest expenses have remained fairly stable due to low interest rates and the perceived low risk of U.S. government default, according to the U.S. Treasury Fiscal Data. This coin is a parody coin about the debt crises in the US and to highlight various aspects about this crises in a humouros way to the people on solana. $USNDC

UnitedStates National Debt Coin

UnitedStates National Debt Coin ($USNDC.X) is trending as community members highlight positive sentiment and strong buying activity. Conversations suggest a potential breakout, with many urging others to buy before a significant price increase. Some users are also discussing the coin's activity and tracking via Phantom wallet.

Mamo turns what used to be complex into easy, human-first routines.  It works quietly in the background, finding smart opportunities for your money while you focus on what matters in your life. Think of Mamo as your knowledgeable friend who understands how to help your money grow and explain everything in plain language.  Behind the scenes, Mamo applies proven strategies and real-time data to optimize your portfolio, reinvest earnings when conditions are right, and adapt to market shifts — all with your approval and full transparency.  No noise. No confusion. Just calm, steady growth.

Mamo

Mamo is trending as the community discusses its potential following a significant price run and subsequent pullback, with attention focused on the anticipated launch of The Base App in Q4. Some community members are speculating on price targets and the potential for substantial user growth once the app is released, while others express concerns about recent price action.

Solana Street Bets is not just a memecoin; it's a symbol of creativity, humor, and the power of a united community. Inspired by the infamous /wallstreetbets subreddit. Solana Street Bets is here to put respect on the Wall St originated memes in the industry. Solana Street Bets is a decentralized Solana meme coin inspired by the infamous /wallstreetbets subreddit.

SatoshiStreetBets

SSB.X is trending as community members highlight a specific associated token, $PUPU.X, with many claiming "dips are getting bought instantly" and momentum is building for a breakout. The project's connection to the broader SatoshiStreetBets community and a comparison to previous meme coin successes like PEPE are also driving interest. Bullish community members suggest that the "rocket fuel is stacking" for the project.

The Render Network is a leading decentralized GPU compute platform for applications ranging from 3D rendering to machine learning and generative AI.  The network connects node operators looking to monetize their idle GPU compute power with artists and developers looking to scale intensive 3D rendering work and machine learning applications in the cloud. Through a decentralized peer-to-peer network, the Render Network achieves unprecedented levels of scale, speed, and economic efficiency. Facilitated by the Render Network Foundation, the ecosystem empowers artists and developers to build services and applications for the emerging digital economy.

Render Token (SOL)

$RENDER.X is trending as users discuss its potential in the AI sector and speculate on possible catalysts. Some community members mention its connection to Grok AI and potential for significant gains, while others analyze its price action and discuss accumulation strategies. Conversations also address the token's migration to Solana and upcoming events like Rendercon.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

Biogen ($BIIB) is trending as traders weigh the impact of a recent FDA roadblock for its Spinraza drug amid ongoing European regulatory reviews. The community is also actively discussing potential support trendlines and call option strategies. Positive sentiment stems from recent EU approval for Zurzuvae, a postpartum depression drug.

Plasma is the layer 1 blockchain building the stablecoin infrastructure for a new global financial system.   It is purpose-built for global stablecoin payments, offering zero-fee USD₮ transfers and custom gas tokens to help realise the stablecoin promise of permissionless access to financial services for everyone, everywhere.   Plasma’s global payments coverage and inbound suite of products position it as the native chain for stablecoin payments.

Plasma

Plasma (XPL.X) is trending amid community discussions about its trading volume and potential connections to other cryptocurrencies. Some traders are suggesting short positions based on technical analysis, while others express concerns about the project's activity and tokenomics, with comparisons being drawn to other stablecoins and yield protocols. The community is also actively speculating about price targets and the potential impact of new exchange listings.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending as investors discuss the company's recent acquisition of anti-coagulant assets, including a Pre-Phase-2 drug, which expands their pipeline. Community members are noting the bullish setup, breakout energy, and building momentum, anticipating a potential upside breakout. The company's advancements in cardiovascular therapeutics and potential impact on the anticoagulation market are also being highlighted.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report?

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

H.C. Wainwright on Tuesday raised its price target on MannKind to $11 from $9 and reiterated its buy rating on the shares, following positive late-stage study results from partner United Therapeutics for its Tyvaso Inhalation Solution.The brokerage firm said the positive data removes “a significant overhang” on MannKind shares and supports a re-rating of the stock toward intrinsic value, with added upside from royalties and cash flows tied to Tyvaso.The call comes after United Therapeutics said Tuesday that its phase 3 TETON-2 trial showed nebulized Tyvaso improved lung function in idiopathic pulmonary fibrosis patients versus placebo in a dose-dependent manner, meeting the trial's primary endpoint.&nbsp;Over 52 weeks, patients on Tyvaso saw lung capacity improve by 95.6 milliliters compared with placebo, a result the company said was highly statistically significant.&nbsp;Benefits were observed across patient subgroups, and significant gains were also reported in quality of life and other secondary measures. The treatment was well-tolerated with no new safety signals.United Therapeutics said it plans to meet with the U.S. Food and Drug Administration before the end of the year to discuss adding IPF to Tyvaso’s label, with additional data from the ongoing TETON-1 study expected in the first half of 2026.Last week, MannKind said that United Therapeutics had exercised an option under their 2018 license and collaboration agreement to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mannkind-united-therapeutics-expand-agreement-to-develop-second-investigational-molecule-together/chsURMTRdkC">develop a second dry powder inhalation therapy</a>. The partnership previously produced Tyvaso DPI, the first FDA-approved dry powder inhalation treatment for pulmonary hypertension, cleared in 2022.MannKind will use its Technosphere platform to formulate a new investigational molecule, while United Therapeutics will conduct preclinical and clinical testing. MannKind will receive $5 million upfront, up to $35 million in milestone payments, and a 10% royalty on sales if the therapy reaches market.&nbsp;On Stocktwits, retail sentiment for both MannKind and United Therapeutics was ‘extremely bullish’ amid ‘extremely high’ message volume.One user speculated that United Therapeutics’ growing ties to MannKind reduce the likelihood of a buyout by another large pharmaceutical company, saying they expect a 13G filing showing a bigger ownership stake.&nbsp;<stembedurl>https://stocktwits.com/Hard2beLong/message/627299899</stembedurl>Another user questioned whether it made more sense for United Therapeutics to continue paying MannKind a 10% royalty stream each year rather than pursue a full acquisition.<stembedurl>https://stocktwits.com/Lazarus2024/message/627294687</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/MNKD">MannKind’s stock</a> has declined 10.7% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/UTHR">United Therapeutics’ stock</a> has risen 14.7% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

H.C. Wainwright on Tuesday raised its price target on MannKind (MNKD) to $11 from $9 and reiterated its buy rating on the shares. (Photo credit: Getty Images)

MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results 

United Therapeutics plans to meet with the U.S. FDA before the end of the year to discuss adding idiopathic pulmonary fibrosis to Tyvaso’s label.

Equity

MannKind Corporation (MNKD) on Wednesday said that it will formulate a dry powder inhalation therapy, and United Therapeutics (UTHR) will conduct preclinical and clinical development under an expanded agreement.The two companies entered into a licence and collaboration agreement in 2018. The agreement led to the US Food and Drug Administration’s approval of Tyvaso DPI in May 2022 and included an option for United Therapeutics to expand the license to include additional active ingredients. Tyvaso DPI was the first FDA-approved dry powder inhalation treatment for pulmonary hypertension.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MNKD">MNKD</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels. Shares of MNKD traded 5% higher in the pre-market session at the time of writing.Meanwhile, retail sentiment around <a href="https://stocktwits.com/symbol/UTHR">UTHR</a> stayed within ‘neutral’ territory, coupled with ‘low’ levels of retail chatter.MannKind CEO Michael Castagna <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/27/3139981/29517/en/MannKind-Announces-Expansion-of-United-Therapeutics-Collaboration-for-Second-Inhaled-Therapy.html">said</a> that this next step in the collaboration between the two companies strengthens the existing partnership and the versatility of its dry powder formulations.The company said that it will receive an upfront payment of $5 million under the expanded agreement. It is also eligible to receive up to $35 million milestone payments and 10% royalties on net sales of resulting products.Formulation and development activities for the new investigational molecule will begin immediately, the company said. It will be formulated using MannKind’s proprietary Technosphere inhalation technology.While MNKD stock is down by 37% this year, UTHR stock is down by 12%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-recalls-nearly-356000-vehicles-in-us/chsUG1SRdkx">Ford Issues Nearly 356,000 Vehicles Recall In U.S., But Retail Investors Spot Emerging Catalysts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together

The 2018 agreement between the companies led to US FDA approval of Tyvaso DPI in May 2022 and included an option for United Therapeutics to expand the license to include additional active ingredients. 

New Strong Sell Stocks for August 27th

CVGI, INBK and MNKD have been added to the Zacks Rank #5 (Strong Sell) List on August 27, 2025.

Wall Street issued mixed calls on scPharmaceuticals on Monday after MannKind said it would buy the former in a deal that could total $360 million, or approximately $6.35 per share if all milestones are met.&nbsp;The deal represents a 31% premium to scPharma’s last closing price before the announcement.After the news, Craig-Hallum pulled back its rating on scPharmaceuticals, shifting it from ‘Buy’ to ‘Hold’ and setting a price target of $6.&nbsp;Craig-Hallum noted that shareholders are entitled to receive $5.35 in cash per share, along with the potential to receive up to an additional $1 in cash per share from future milestone payments and the firm expects a majority of the CVR value to be paid out over time.Maxim Group also downgraded scPharmaceuticals to ‘Hold’ from ‘Buy’ following the acquisition agreement under the same terms.By contrast, H.C. Wainwright reiterated a ‘Buy’ rating on MannKind with a $9 price target, saying the acquisition strengthens MannKind’s revenue base and expands its reach into cardiorenal medicine. The firm described the price paid as “very reasonable.”The acquisition gives&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mannkind-corporation-to-acquire-scpharmaceuticals/chssVp5Rd1m">MannKind access to Furoscix</a>, scPharma’s FDA-approved on-body infuser delivering furosemide to treat fluid overload in patients with chronic heart failure and chronic kidney disease.&nbsp;MannKind estimates Furoscix has a total addressable U.S. market of more than $10 billion.scPharma has been expanding its commercial footprint, reporting $27.8 million in net sales for the first half of 2025, a 96% increase year over year, driven by a larger sales force, growth in nephrology, and new integrated delivery network accounts.&nbsp;Its Furoscix ReadyFlow Autoinjector is expected to be filed for FDA approval in the third quarter of 2025, potentially reducing administration time from five hours to less than 10 seconds.The deal is expected to close in the fourth quarter of 2025 pending regulatory approval.&nbsp;At closing, MannKind will also repay and retire scPharma’s credit facility and revenue-sharing obligations to Perceptive, totaling about $81 million if completed by Sept. 30, 2025.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.On Stocktwits, retail sentiment was ‘extremely bullish’ for scPharmaceuticals with ‘extremely high’ message volume, while sentiment for MannKind was ‘bullish’ with ‘high’ message volume.One user remarked that it was unusual to see a smaller company like MannKind buying a larger one, calling the deal “bizarro territory.”<stembedurl>https://stocktwits.com/Kuka/message/626521368</stembedurl>Another user noted that the acquisition would eliminate scPharmaceuticals’ heavy sales and marketing costs, saying they were beginning to appreciate the efficiency gains MannKind could achieve by folding those operations into its own.<stembedurl>https://stocktwits.com/oneyedjacks/message/626485594</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/SCPH">scPharmaceuticals’ stock</a> has risen nearly 56% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/MNKD">MannKind’s stock</a> has declined nearly 40% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

MannKind (MNKD) said it would buy scPharmaceuticals (SCPH) in a deal that could total $360 million, or approximately $6.35 per share if all milestones are met. (Photo credit: Getty Images)

MannKind’s $360M scPharma Deal Splits Analysts — Retail Traders Call It ‘Bizarro Territory’ But Stay Bullish

The deal hands MannKind access to scPharma’s Furoscix heart and kidney therapy, a product with a U.S. market potential estimated at over $10 billion.

MannKind Corporation (MNKD) will acquire scPharmaceuticals Inc. (SCPH) in a deal worth up to approximately $360 million, the companies announced on Monday.Under the merger agreement, MannKind will commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals common stock for $5.35 per share in cash at closing, in addition to one contingent value right worth up to $1. The non-tradeable CVR is payable upon achieving certain regulatory and net sales milestones, the companies <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-acquire-scpharmaceuticals-accelerating-revenue-growth">said</a>.The total per-share consideration of up to $6.35 represents a premium of about 31% to SCPH’s closing price on Friday. The transaction is expected to close in the fourth quarter of 2025, subject to necessary approvals.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MNKD">MannKind</a> stayed within ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels. Meanwhile, sentiment around <a href="https://stocktwits.com/symbol/SCPH">SCPH stock</a> jumped from ‘neutral’ to ‘bullish’ territory, accompanied by ‘low’ levels of retail chatter. While shares of MannKind traded 5% lower in the pre-market session, SCPH stock traded 13% higher.scPharmaceuticals currently markets Furoscix, an FDA-approved on-body infuser delivering Furosemide, used to treat fluid overload in adult patients with chronic heart failure (CHF) and chronic kidney disease (CKD). MannKind, which estimates Furoscix has a total addressable market of over $10 billion in the U.S., said that the acquisition will expand its reach into cardiorenal medicine.MannKind also stated that the combined company is expected to have a stronger revenue base with three commercial assets, including Furoscix.While MNKD stock is down by 36% this year, SCPH stock is up by 37%.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/alibaba-stock-sees-retail-chatter-spike-340-ahead-of-earnings/chssFwcRd1Y">Alibaba Stock Sees Retail Chatter Spike 340% Ahead Of Earnings: AI Investment And E-Commerce In Focus</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

MannKind Corporation to Acquire scPharmaceuticals: More Details Inside

MannKind Corporation (MNKD) will acquire scPharmaceuticals Inc. (SCPH) in a deal worth up to approximately $360 million, the companies announced on Monday.

The transaction is expected to close in the fourth quarter of 2025, subject to necessary approvals.

MannKind (MNKD) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

MannKind Corporation (MNKD) said on Wednesday that it has entered into up to $500 million strategic financing agreement with funds managed by Blackstone (BX) after its second-quarter (Q2) revenue missed Wall Street expectations.“The funding will support the expansion of our commercial team in preparation for the anticipated launch of the pediatric indication for Afrezza, if approved, continued pipeline advancement, potential business development opportunities, and general corporate purposes,” MannKind CEO Michael Castagna <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-and-blackstone-announce-500-million-strategic-financing">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MNKD">MNKD</a> jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:624/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_06_at_8_42_13_AM_png_d534b5d4d1.webp" alt="MNKD's Sentiment Meter and Message Volume as of 8:24 a.m. ET on Aug. 6, 2025 | Source: Stocktwits" width="624" height="63"><figcaption>MNKD's Sentiment Meter and Message Volume as of 8:24 a.m. ET on Aug. 6, 2025 | Source: Stocktwits</figcaption></figure>Afrezza is an inhaled insulin that starts lowering blood sugars in about 12 minutes for adults living with type 1 or type 2 diabetes. The company is now looking to expand its use to pediatric patients, and a U.S. Food and Drug Administration ruling on the application is expected in early our third quarter.The up to $500 million senior secured credit facility consists of a $75 million initial term loan funded at closing, a $125 million delayed draw term loan (DDTL) available for the next 24 months, subject to customary drawdown conditions, and an additional $300 million uncommitted DDTL available at the mutual agreement of MannKind and Blackstone.MNKD stock is down by 40% this year and by about 24% over the past 12 months.A Stocktwits user opined that the stock is ‘ridiculously undervalued’.<stembedurl>https://stocktwits.com/Keeportrade/message/623911248</stembedurl>Another opined that they were hoping for a partnership announcement from the company over a loan.<stembedurl>https://stocktwits.com/Jaketom/message/623908336</stembedurl>MannKind on Wednesday reported Q2 revenues of $76.5 million, marking a growth of 6% year-on-year (YoY) but below an analyst estimate of $77.82 million. &nbsp;&nbsp;&nbsp;&nbsp;The YoY increase was spurred by an increase in royalties and Afrezza revenue, which offset a decline in collaborations and services revenues and a dip in net revenue for V-Go, the company's wearable insulin delivery device.Adjusted net income came in at $0.05 for the three months through the end of June, in line with estimates.MNKD stock is down by 38% this year and by 24% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rivian-plans-shut-down-of-illinois-plant-for-three-weeks/chr1UQZRd5b">Rivian Plans Shut Down Of Illinois Plant For Three Weeks, R2 Hopes Sparks Mixed Reactions Among Retail Investors</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

MannKind Announces $500M Financing Agreement With Blackstone After Q2 Revenue Miss: Retail Believes Stock Is ‘Ridiculously Undervalued’

MannKind will receive $75 million in cash at the closing of the agreement. 

MannKind (MNKD) Reports Break-Even Earnings for Q2

MannKind (MNKD) delivered earnings and revenue surprises of -100.00% and -2.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

ABCELLERA BIOLG (ABCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

MNKD
Mannkind Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MNKD News

MNKD Mannkind Corp